TRISALUS LIFE SCIENCES INC (TLSI) Stock News

TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates

TriSalus Life Sciences, Inc. (TLSI) delivered earnings and revenue surprises of -65% and 1.04%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Mentions: CGC

TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance

Earnings Scheduled For May 15, 2025

Mentions: ACOG SANW NRXP FTLF ...

Examining the Future: TriSalus Life Sciences's Earnings Outlook

OrganiGram (OGI) Reports Q2 Loss, Beats Revenue Estimates (Revised)

OrganiGram (OGI) delivered earnings and revenue surprises of -66.67% and 8.09%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Mentions: OGI

TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call

OrganiGram (OGI) Reports Q2 Loss, Misses Revenue Estimates

OrganiGram (OGI) delivered earnings and revenue surprises of -333.33% and 29.59%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Mentions: OGI

TerrAscend Corp. (TSNDF) Reports Q1 Loss, Lags Revenue Estimates

TerrAscend Corp. (TSNDF) delivered earnings and revenue surprises of -66.67% and 0.89%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results

TriSalus Life Sciences’ Q4 Loss Exceeds Projections, Revenue Tops Estimates – Retail Stays Pessimistic

The company reaffirmed its previous guidance for 2025 and said it expects sales growth of over 50% and its gross margin to exceed 87%, higher than the 86% reported for 2024.

Mentions: DWX IMFL

TriSalus Life Sciences, Inc. (TLSI) Reports Q4 Loss, Tops Revenue Estimates

TriSalus Life Sciences, Inc. (TLSI) delivered earnings and revenue surprises of 0% and 1.24%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Mentions: ABT

TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update

TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping

TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”

3 Stocks With Robust Growth Outlooks Insiders Are Buying

Insiders are buying these three stocks. The underlying companies have robust growth outlooks and are on track to deliver in 2025.

Mentions: SFD AVDL

TriSalus Life Sciences Announces Key Appointments to Board of Directors

TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed

TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call

TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System

TriSalus Announces Leadership Changes

TriSalus Reports Q3 2024 Financial Results and Provides Business Update

TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer

TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment

TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call

TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit

TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System

TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q2 2024

TLSI stock results show that TriSalus Life Sciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

TriSalus Reports Q2 2024 Financial Results and Business Update

TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call

TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants